Letter to Shareholders announcing Licensing of Genetic Networks IP and Tech

LETTER TO SHAREHOLDERS: July 2, 2024

We're thrilled to announce a groundbreaking partnership between Category V Biotech, Inc. (OTC: CATV), formerly known as 4Cable TV International, Inc and Genetic Networks. This agreement gives Category V Biotech the exclusive license for all Genetic Networks intellectual property and technology worldwide for cannabis applications.

Key Highlights:

1. Exclusive Licensing of GeneScape™: The cutting-edge platform that will be utilized by Category V Biotech to identify optimal drug compounds through whole-genome analysis, accelerating drug discovery and development.
2. Collaboration on Cannabis R&D: This partnership positions both companies at the forefront of developing cannabis medicines. We'll be leveraging extensive disease data to map out beneficial medicinal targets per product.
3. Regulatory Advancements: The recent rescheduling of cannabis in the U.S. paves the way for new opportunities, enabling us to drive innovation and advance therapeutic solutions for patients.

We're excited to unlock the full potential of cannabis-based therapeutics and bring novel treatments to patients faster than ever.  Instead of waiting until the acquisition is completed, we can start now with the Exclusive Licensing Agreement that was signed. Stay tuned for more updates as we embark on this transformative journey!

Sincerely,

MICHAEL FELDENKRAIS, CEO